In patients with metastatic colorectal cancer (mCRC) lacking KRAS mutations, bevacizumab or cetuximab in combination with either FOLFOX or FOLFIRI chemotherapy provides similar overall survival of 29 months, indicating a new benchmark for patients with this disease. The adverse events for the two arms were as expected for the two classes of targeted therapies. As 73% of patients received FOLFOX and 27% FOLFIRI, comparisons between the arms in terms of chemotherapy regimen were not possible. Nonetheless, these results provide several options for patients with metastatic CRC.
References
Venook, A. P. et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacixumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum [abstract]. ASCO Annual Meeting 2014 LBA3 (2014)
Rights and permissions
About this article
Cite this article
Cetuximab or bevacizumab with chemo: take your pick. Nat Rev Clin Oncol 11, 380 (2014). https://doi.org/10.1038/nrclinonc.2014.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.107
